Side-by-side · Research reference

5-Amino-1MQvsCrystagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongAUTO-DRAFTED8/38 cited

BAnimal-MechanisticHUMAN-REVIEWED12/40 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

01Mechanism of Action

Parameter

5-Amino-1MQ

Crystagen

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

B-lymphocytes in splenic tissueСhervyakova 2014

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

B-cell activation → Immune modulation during agingСhervyakova 2014

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Feedback intact?

—

Unknown — bioregulator mechanism not fully characterized

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Antibody development

—

02Dosage Protocols

Parameter

5-Amino-1MQ

Crystagen

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

Frequency

Once daily, fasted

Unknown — bioregulator protocols variable

Lower / starter dose

50 mg / day

—

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

Animal / mechanistic

Duration

8–12 weeks per cycle

Unknown — chronic administration presumed in animal models

Form

Oral capsule

—

Timing

Morning fasted preferred

—

Half-life

Hours (estimated; no human PK published)

Not reported

Route

—

Subcutaneous (presumed from bioregulator class)

04Side Effects & Safety

Parameter

5-Amino-1MQ

Crystagen

GI symptoms

Mild nausea (anecdotal)

—

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

—

Cancer risk

Unclear — NNMT also studied in oncology contexts

—

Pregnancy / OB

Avoid

—

Drug interactions

Theoretical with niacin / B-vitamin supplements

—

Published adverse events

—

None reported in available animal literature

Human safety data

—

Absent — no controlled human trials identified

Autoimmune considerations

—

Theoretical concern with B-cell modulators in predisposed individuals

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

Crystagen

·Active autoimmune disease (theoretical)

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

05Administration Protocol

Parameter

5-Amino-1MQ

Crystagen

1. Form

Oral capsule. No injection.

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

2. Administration

Take with water, fasted preferred.

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

3. Timing

Morning fasted.

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

4. Storage

Room temp ≤25 °C, dry place.

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

5. Caveat

Monitor B-vitamin status with chronic use.

—

06Stack Synergy

5-Amino-1MQ

— no documented stacks

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014